# Valproate as First Line Therapy in Combination With Rituximab and CHOP in Diffuse Large B-cell Lymphoma

> **NCT01622439** · PHASE1,PHASE2 · COMPLETED · sponsor: **Lund University Hospital** · enrollment: 50 (actual)

## Conditions studied

- Diffuse Large B-cell Lymphoma

## Interventions

- **DRUG:** Valproate
- **DRUG:** Rituximab
- **DRUG:** Cyclophosphamide
- **DRUG:** Doxorubicin
- **DRUG:** Vincristine
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT01622439
- **Lead sponsor:** Lund University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06
- **Primary completion:** 2018-03
- **Final completion:** 2018-03
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2018-03-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01622439

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01622439, "Valproate as First Line Therapy in Combination With Rituximab and CHOP in Diffuse Large B-cell Lymphoma". Retrieved via MORVS 2026-09-29 from https://api.morvs.ai/clinical/NCT01622439. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*